{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:16:13Z","timestamp":1793812573395,"version":"4.6.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T00:00:00Z","timestamp":1721174400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003625","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["HI17C2206"],"award-info":[{"award-number":["HI17C2206"]}],"id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003625","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["HA22C0012"],"award-info":[{"award-number":["HA22C0012"]}],"id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003645","name":"National Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003645","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.esmoop.2024.103668","type":"journal-article","created":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T12:15:13Z","timestamp":1724933713000},"page":"103668","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["A phase II study of tepotinib in patients with advanced solid cancers harboring MET exon 14 skipping mutations or amplification (KCSG AL19-17)"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0702-3400","authenticated-orcid":false,"given":"E.J.","family":"Kang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1773-134X","authenticated-orcid":false,"given":"Y.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5037-0523","authenticated-orcid":false,"given":"Y.J.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.M.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.-J.","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.J.","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6145-4426","authenticated-orcid":false,"given":"T.M.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.K.","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.-C.","family":"Jeung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.I.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2562-9257","authenticated-orcid":false,"given":"S.Y.","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.K.","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.H.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.H.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2024.103668_bib1","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0378-1119(98)00264-9","article-title":"The human hepatocyte growth factor receptor gene: complete structural organization and promoter characterization","volume":"215","author":"Liu","year":"1998","journal-title":"Gene"},{"key":"10.1016\/j.esmoop.2024.103668_bib2","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/339155a0","article-title":"Tyrosine kinase receptor indistinguishable from the c-met protein","volume":"339","author":"Giordano","year":"1989","journal-title":"Nature"},{"key":"10.1016\/j.esmoop.2024.103668_bib3","doi-asserted-by":"crossref","first-page":"497","DOI":"10.6004\/jnccn.2022.0025","article-title":"Non-small cell lung cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology","volume":"20","author":"Ettinger","year":"2022","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.esmoop.2024.103668_bib4","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1080\/14737140.2019.1643239","article-title":"Capmatinib for the treatment of non-small cell lung cancer","volume":"19","author":"Vansteenkiste","year":"2019","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.esmoop.2024.103668_bib5","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/s41571-020-0377-z","article-title":"MET-dependent solid tumours - molecular diagnosis and targeted therapy","volume":"17","author":"Guo","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.esmoop.2024.103668_bib6","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMoa2004407","article-title":"Tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations","volume":"383","author":"Paik","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2024.103668_bib7","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa2002787","article-title":"Capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer","volume":"383","author":"Wolf","year":"2020","journal-title":"New Engl J Med"},{"key":"10.1016\/j.esmoop.2024.103668_bib8","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1158\/1078-0432.CCR-21-1566","article-title":"FDA approval summary: capmatinib and tepotinib for the treatment of metastatic NSCLC harboring MET exon 14 skipping mutations or alterations","volume":"28","author":"Mathieu","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2024.103668_bib9","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1158\/2159-8290.CD-21-1064","article-title":"Genomic landscape and clinical utility in Korean advanced pan-cancer patients from prospective clinical sequencing: K-MASTER program","volume":"12","author":"Park","year":"2022","journal-title":"Cancer Discov"},{"key":"10.1016\/j.esmoop.2024.103668_bib10","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.12003","article-title":"Prevalence of clonal hematopoiesis of indeterminate potential (CHIP) measured by an ultra-sensitive sequencing assay: exploratory analysis of the Circulating Cancer Genome Atlas (CCGA) study","volume":"36","author":"Swanton","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2024.103668_bib11","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.3390\/cancers12082277","article-title":"Clonal hematopoiesis in liquid biopsy: from biological noise to valuable clinical implications","volume":"12","author":"Chan","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.esmoop.2024.103668_bib12","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1002\/1878-0261.12727","article-title":"Clinical significance of clonal hematopoiesis in the interpretation of blood liquid biopsy","volume":"14","author":"Chan","year":"2020","journal-title":"Mol Oncol"},{"key":"10.1016\/j.esmoop.2024.103668_bib13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1004873","article-title":"CNVkit: genome-wide copy number detection and visualization from targeted DNA sequencing","volume":"12","author":"Talevich","year":"2016","journal-title":"Plos Comput Biol"},{"key":"10.1016\/j.esmoop.2024.103668_bib14","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2024.103668_bib15","article-title":"Long-term efficacy, safety, and subgroup analysis of savolitinib in Chinese patients with NSCLCs harboring MET exon 14 skipping alterations","volume":"3","author":"Lu","year":"2022","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.esmoop.2024.103668_bib16","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw262","article-title":"Exon 14 deleted MET receptor as a new biomarker and target in cancers","volume":"109","author":"Cortot","year":"2017","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.esmoop.2024.103668_bib17","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/annonc\/mdw199.36","article-title":"MET activation via exon 14 skipping mutations (METex14del): gastrointestinal prevalence and sensitivity to MET inhibitor AMG337","volume":"27","author":"Cecchi","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2024.103668_bib18","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.3_suppl.329","article-title":"Activity of tepotinib in hepatocellular carcinoma (HCC) with high-level amplification (amp): preclinical and clinical evidence","volume":"39","author":"Faivre","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2024.103668_bib19","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.e16037","article-title":"Responses to the MET inhibitor tepotinib in gastric cancers with MET amplification or both high PD-L1 expression and an MET exon 14 skipping mutation","volume":"40","author":"Zang","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2024.103668_bib20","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.jtho.2021.02.010","article-title":"Crizotinib in patients with MET-amplified NSCLC","volume":"16","author":"Camidge","year":"2021","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.esmoop.2024.103668_bib21","article-title":"Tepotinib in patients with non-small cell lung cancer with high-level MET amplification detected by liquid biopsy: VISION Cohort B","volume":"4","author":"Le","year":"2023","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.esmoop.2024.103668_bib22","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1093\/abbs\/gmab026","article-title":"Amplification and expression of c-MET correlate with poor prognosis of patients with gastric cancer and upregulate the expression of PDL1","volume":"53","author":"Yang","year":"2021","journal-title":"Acta Biochim Biophys Sin"},{"key":"10.1016\/j.esmoop.2024.103668_bib23","article-title":"Prognostic significance of MET amplification and expression in gastric cancer: a systematic review with meta-analysis","volume":"9","author":"Peng","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.esmoop.2024.103668_bib24","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1097\/JTO.0000000000000443","article-title":"Dynamic plasma EGFR mutation status as a predictor of EGFR-TKI efficacy in patients with EGFR-mutant lung adenocarcinoma","volume":"10","author":"Tseng","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.esmoop.2024.103668_bib25","doi-asserted-by":"crossref","first-page":"6984","DOI":"10.18632\/oncotarget.6874","article-title":"Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02)","volume":"7","author":"Lee","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.esmoop.2024.103668_bib26","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1016\/j.jtho.2019.08.003","article-title":"Monitoring therapeutic response and resistance: analysis of circulating tumor DNA in patients with ALK+ lung cancer","volume":"14","author":"Horn","year":"2019","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.esmoop.2024.103668_bib27","first-page":"1047","article-title":"Concomitant TP53 mutation confers worse prognosis in EGFR-mutated non-small cell lung cancer patients treated with TKIs","volume":"9","author":"Canale","year":"2020","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.esmoop.2024.103668_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2023.103929","article-title":"Meta-analysis of the prognostic impact of TP53 co-mutations in EGFR-mutant advanced non-small-cell lung cancer treated with tyrosine kinase inhibitors","volume":"184","author":"Ferrara","year":"2023","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.esmoop.2024.103668_bib29","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1093\/annonc\/mdy333","article-title":"Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer","volume":"29","author":"Kron","year":"2018","journal-title":"Ann Oncol"}],"updated-by":[{"DOI":"10.1016\/j.esmoop.2025.104302","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000}}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702924014376?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702924014376?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T15:34:46Z","timestamp":1727364886000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702924014376"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S2059702924014376"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.103668","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase II study of tepotinib in patients with advanced solid cancers harboring MET exon 14 skipping mutations or amplification (KCSG AL19-17)","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.103668","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"103668"}}